Around the world over thousands of years, patients have received root-cause holistic treatment for their diseases with personalized
treatment, diet and lifestyle modification recommendations. Read the inspiring true stories of practitioners who heal people and who recovered
from their problems after dementia treatment at their clinics. Many have been generous to share their knowledge and experience for the benefit
of other holistic experts and patients alike. Many practitioners share their Case Studies and the healing powers of dementia and related therapies
as they heal people who benefited from our expertise.
Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials.
June 2015
/ onclick=”MoreLine(‘11687’, ‘Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials.’)”>
…more

/>Wien Med Wochenschr. 2015 Jun 20. Epub 2015 Jun 20. PMID: 26092515
Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial.
January 2007
In previous trials of the Ginkgo biloba special extract EGb 761 improvements in cognitive functioning and behavioural symptoms were found in patients with aging-associated cognitive impairment or dementia. This trial was undertaken to assess the efficacy of EGb 761 in mild to moderate dementia with neuropsychiatric features.
METHODS:
Double-blind trial including 400 patients aged 50 years or above with Alzheimer’s (AD) or vascular dementia (VaD), randomized to receive EGb 761 or placebo for 22 weeks. Patients scored below 36 on the Test for the Early Detection of Dementia with Discrimination from Depression (TE4D), between 9 and 23 on the SKT test battery and at least 5 on the Neuropsychiatric Inventory (NPI).
Results:
There was a mean -3.2-point improvement in the SKT upon EGb 761 treatment and an average deterioration by +1.3 points on placebo (p < 0.001, two-sided, ANOVA). EGb 761 was significantly superior to placebo on all secondary outcome measures, including the NPI and an activities-of-daily-living scale. Treatment results were essentially similar for AD and VaD subgroups. The drug was well tolerated; adverse events were no more frequent under drug than under placebo treatment.
Conclusion:
The data add further evidence on the safety and efficacy of EGb 761 in the treatment of cognitive and non-cognitive symptoms of dementia.
/ onclick=”MoreLine(‘11686’, ‘Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial.’)”>
…more

/>Arzneimittelforschung. 2007;57(1):4-11. PMID: 17341003
Physical activity and inflammation: effects on gray-matter volume and cognitive decline in aging.
May 2016
/ onclick=”MoreLine(‘9313’, ‘Physical activity and inflammation: effects on gray-matter volume and cognitive decline in aging.’)”>
…more

/>Hum Brain Mapp. 2016 May 9. Epub 2016 May 9. PMID: 27159568
Diet and Alzheimer’s risk factors or prevention: the current evidence.
May 2011
/ onclick=”MoreLine(‘8369’, ‘Diet and Alzheimer’s risk factors or prevention: the current evidence.’)”>
…more

/>Expert Rev Neurother. 2011 May ;11(5):677-708. PMID: 21539488